Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CITADEL-302
jRCT2031210296Completed
- Sponsor
- Incyte
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of parsaclisib in follicular lymphoma (FL), marginal zone B-cell lymphoma (MZL), nodal marginal zone B-cell lymphoma (NMZL) and 2 more (2 arms), sponsored by Incyte. Primary endpoint: Progression Free Survival (PFS) in R/R FL and MZL participants. Started Dec 2022; status: completed.
02
Drugs
parsaclisib
03
Conditions
follicular lymphoma (FL)marginal zone B-cell lymphoma (MZL)nodal marginal zone B-cell lymphoma (NMZL)splenic marginal zone lymphoma (SMZL)extranodal marginal zone B-cell lymphoma (EMZL)
Beyond the preview
Go deeper on jRCT2031210296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210296.